Car T-Cell Therapy

Infection mitigation with vaccines is essential for patients with hematologic malignancies because they are at increased risk for severe infection, hospitalization and mortality if they contract COVID-19.

There are many frustrating aspects to a cancer diagnosis.

Younger patients with acute lymphoblastic leukemia who do not respond to CD19-directed chimeric antigen receptor T-cell therapy exhibit certain gene regulation patterns that may be associated with treatment resistance, study results show.

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

Early phase 1 trial results using an investigational chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.

The FDA granted fast track designation to PRGN-3006 for the treatment of adults with relapsed or refractory acute myeloid leukemia.

The FDA approved axicabtagene ciloleucel as second-line treatment for adults with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or experienced disease relapse within 12 months of initial treatment.

The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.

Commercially available chimeric antigen receptor T cells for acute myeloid leukemia could be just a few years away, according to a presenter at the inaugural Personalizing Pediatric Cancer Care Summit.

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.